Latest Intelligence on General Business in United Kingdom

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

American Airlines/BA: Oneworld starts to crack

There are fears that the collapse of the BA-AA merger will also kill the Oneworld alliance that they spearhead: other carriers could well defect to alternative alliances that have the antitrust immunity Oneworld lacks. This leaves BA facing an unpleasant choice: sacrificing 224 extremely valuable Heathrow slots, or risking losing its alliance altogether.

Published By Datamonitor
18 Feb 2002
CommentWire
CommentWire

American Express: passport, tickets...shares?

Published By Datamonitor
25 Jul 2001
CommentWire
CommentWire

AMP/III: Aussies to shell out for a lame duck

Published By Datamonitor
02 Jul 2001
CommentWire
CommentWire

AMP: facing facts

Australian Life insurer and fund manager AMP has announced its plan to spin off its UK business in a plan to revive the group's flagging fortunes and concentrate on its core domestic market. If current market conditions continue, other companies may make similar plans.

Published By Datamonitor
01 May 2003
CommentWire
CommentWire

Anglian Water: splitting to put company on right track

Published By Datamonitor
23 Nov 2000
CommentWire
CommentWire

Anheuser-Busch: buying presence in a growing market

Anheuser-Busch's acquisition of Goose Island marks a change in tack for the brewer that has previously focused on bringing its own ales to the market under the Budweiser name. Perhaps sensing that this branding lacked the necessary authenticity with consumers, it has turned to acquiring a brewer in an element of the market that will be vitally important in the future.

Published By Datamonitor
05 Apr 2011
CommentWire
CommentWire

Antidepressants: all is not well

Clever marketing and media coverage has helped to de-stigmatize depression. Diagnosis rates have soared and UK antidepressant prescriptions have doubled in the last 10 years. However, there are concerns over their effectiveness and safety. Drug companies need to overcome these concerns if they are to benefit from the rising demand.

Published By Datamonitor
01 Mar 2002
ResearchWire
ResearchWire

Antidepressants: noradrenergics sales to rise

Published By Datamonitor
15 Mar 2001
CommentWire
CommentWire

Antidepressants: the questions continue

The expert panel assembled to review the safety of SSRIs, used in the treatment of depression, has been dissolved and a new team will be appointed. The decision means further delays for the results of the study and ongoing questions as to the safety of the SSRIs.

Published By Datamonitor
02 Apr 2003
ResearchWire
ResearchWire

Antimetabolites: market will be worth $1.9 billion in 2007

Published By Datamonitor
12 Jun 2001

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.